To cite this paper use one of the standards below:
Transthyretin (TTR) is an homotetrameric protein involved in the transport of thyroid hormones and is also capable of binding to retinol binding protein. More than 150 different mutations have been described in the TTR gene, many associated with amyloidosis conditions such as familial amyloidotic cardiomyopathy (FAC), a progressive and fatal disease. Recently, our group, in partnership with HUCFF, described a new variant in a Brazilian family that causes CAF: A39D-TTR. The position 39 is located in the AB loop, a region involved in tetramer formation and in the thyroxine-binding channel. Because of this, our main objective was to express, purify and characterize the structure of the new variant A39D-TTR to understand its implications to FAC. During the purification process, using size exclusion chromatography (SEC) and other biophysical techniques, we characterized the A39D-TTR variant as a dimer and not a tetramer. In collaboration with Prof. Dr. Humberto Pereira (USP), we determined its structure by X-ray crystallography, and the proximity of the four aspartic acids in the tetrameric structure was evident, which prevents the formation of tetramers. The stability of the new variant was evaluated using high hydrostatic pressure, urea denaturation and binding to bis-ANS (4,4'-Dianilino-1,1'-Binaphthyl-5,5'-Disulfonic Acid, Dipotassium Salt). The low stability of the dimers was evident when compared with the WT-TTR (Wild Type). We also observed the formation of a partially unfolded dimer in the presence of low concentrations of urea (up to 2.5 M). Furthermore, we evaluated its aggregation kinetics at different pH values by absorbance at 330 nm and binding to Thioflavin T, and the formed aggregates were analyzed by transmission electron microscopy, results that demonstrated that A39D-TTR is more amyloidogenic than WT-TTR. We also evaluated the effect of aggregation inhibitors such as diclofenac, that has proven to inhibit the aggregation of A39D-TTR even though this dimeric mutation is incapable to form the thyroxine binding channel, the preferential binding region of this compound. This dataset led us to conclude that A39D-TTR is a dimer in solution, which leads to faster aggregation kinetics than WT-TTR. Furthermore, A39D-TTR aggregation can be mitigated by TTR structural stabilizers, suggesting a possible treatment for FAC caused by the A39D-TTR variant.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper